Sensory integration therapy versus usual care for sensory processing difficulties in autism spectrum disorder in children: study protocol for a pragmatic randomised controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
11 Feb 2019
Historique:
received: 05 12 2018
accepted: 17 01 2019
entrez: 13 2 2019
pubmed: 13 2 2019
medline: 14 6 2019
Statut: epublish

Résumé

Autism spectrum disorder (ASD) is a common lifelong condition affecting 1 in 100 people. ASD affects how a person relates to others and the world around them. Difficulty responding to sensory information (noise, touch, movement, taste, sight) is common, and might include feeling overwhelmed or distressed by loud or constant low-level noise (e.g. in the classroom). Affected children may also show little or no response to these sensory cues. These 'sensory processing difficulties' are associated with behaviour and socialisation problems, and affect education, relationships, and participation in daily life. Sensory integration therapy (SIT) is a face-to-face therapy or treatment provided by trained occupational therapists who use play-based sensory-motor activities and the just-right challenge to influence the way the child responds to sensation, reducing distress, and improving motor skills, adaptive responses, concentration, and interaction with others. With limited research into SIT, this protocol describes in detail how the intervention will be defined and evaluated. This is a two-arm pragmatic individually 1:1 randomised controlled trial with an internal pilot of SIT versus usual care for primary school aged children (aged 4 to 11 years) with ASD and sensory processing difficulties; 216 children will be recruited from multiple sources. Therapy will be delivered in clinics meeting full fidelity criteria for manualised SIT over 26 weeks (face-to-face sessions: two per week for 10 weeks, two per month for 2 months; telephone call: one per month for 2 months). Follow-up assessments will be completed at 6 and 12 months post-randomisation. Prior to recruitment, therapists will be invited to participate in focus groups/interviews to explore what is delivered as usual care in trial regions; carers will be invited to complete an online survey to map out their experience of services. Following recruitment, carers will be given diaries to record their contact with services. Following intervention, carer and therapist interviews will be completed. Results of this trial will provide high-quality evidence on the clinical and cost effectiveness of SIT aimed at improving behavioural, functional, social, educational, and well-being outcomes for children and well-being outcomes for carers and families. ISRCTN14716440 . Registered on 8 November 2016.

Sections du résumé

BACKGROUND BACKGROUND
Autism spectrum disorder (ASD) is a common lifelong condition affecting 1 in 100 people. ASD affects how a person relates to others and the world around them. Difficulty responding to sensory information (noise, touch, movement, taste, sight) is common, and might include feeling overwhelmed or distressed by loud or constant low-level noise (e.g. in the classroom). Affected children may also show little or no response to these sensory cues. These 'sensory processing difficulties' are associated with behaviour and socialisation problems, and affect education, relationships, and participation in daily life. Sensory integration therapy (SIT) is a face-to-face therapy or treatment provided by trained occupational therapists who use play-based sensory-motor activities and the just-right challenge to influence the way the child responds to sensation, reducing distress, and improving motor skills, adaptive responses, concentration, and interaction with others. With limited research into SIT, this protocol describes in detail how the intervention will be defined and evaluated.
METHODS METHODS
This is a two-arm pragmatic individually 1:1 randomised controlled trial with an internal pilot of SIT versus usual care for primary school aged children (aged 4 to 11 years) with ASD and sensory processing difficulties; 216 children will be recruited from multiple sources. Therapy will be delivered in clinics meeting full fidelity criteria for manualised SIT over 26 weeks (face-to-face sessions: two per week for 10 weeks, two per month for 2 months; telephone call: one per month for 2 months). Follow-up assessments will be completed at 6 and 12 months post-randomisation. Prior to recruitment, therapists will be invited to participate in focus groups/interviews to explore what is delivered as usual care in trial regions; carers will be invited to complete an online survey to map out their experience of services. Following recruitment, carers will be given diaries to record their contact with services. Following intervention, carer and therapist interviews will be completed.
DISCUSSION CONCLUSIONS
Results of this trial will provide high-quality evidence on the clinical and cost effectiveness of SIT aimed at improving behavioural, functional, social, educational, and well-being outcomes for children and well-being outcomes for carers and families.
TRIAL REGISTRATION BACKGROUND
ISRCTN14716440 . Registered on 8 November 2016.

Identifiants

pubmed: 30744672
doi: 10.1186/s13063-019-3205-y
pii: 10.1186/s13063-019-3205-y
pmc: PMC6371421
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113

Subventions

Organisme : Department of Health
ID : HTA/15/106/04
Pays : United Kingdom
Organisme : Health Technology Assessment Programme
ID : 15/106/04

Références

J Autism Dev Disord. 2007 May;37(5):894-910
pubmed: 17016677
Qual Life Res. 2006 Aug;15(6):1005-21
pubmed: 16900281
J Autism Dev Disord. 2014 Jul;44(7):1493-506
pubmed: 24214165
JAMA. 2015 Apr 21;313(15):1524-33
pubmed: 25898050
Can J Occup Ther. 1994 Oct;61(4):191-7
pubmed: 10137673
J Autism Dev Disord. 2014 Aug;44(8):1933-45
pubmed: 24577786
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Autism Dev Disord. 2002 Oct;32(5):397-422
pubmed: 12463517
Res Dev Disabil. 2013 Nov;34(11):4210-21
pubmed: 24077070
PLoS One. 2014 Jul 30;9(7):e103038
pubmed: 25075609
J Autism Dev Disord. 2012 Apr;42(4):566-74
pubmed: 21556967
Am J Occup Ther. 2011 Jan-Feb;65(1):76-85
pubmed: 21309374
J Autism Dev Disord. 2014 May;44(5):1103-16
pubmed: 24165702
Autism. 2015 Feb;19(2):133-48
pubmed: 24477447
Am J Occup Ther. 2012 Sep-Oct;66(5):586-94
pubmed: 22917125
Am J Occup Ther. 2007 Mar-Apr;61(2):190-200
pubmed: 17436841
Am J Occup Ther. 2011 Mar-Apr;65(2):133-42
pubmed: 21476360
J Autism Dev Disord. 1992 Sep;22(3):357-73
pubmed: 1383187
Autism. 2012 May;16(3):321-7
pubmed: 22318118

Auteurs

Elizabeth Randell (E)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, UK. RandellE@Cardiff.ac.uk.

Rachel McNamara (R)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, UK.

Sue Delport (S)

School of Healthcare Sciences, Cardiff University, Ty Dewi Sant, Heath Park, Cardiff, UK.

Monica Busse (M)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, UK.

Richard P Hastings (RP)

Centre for Educational Development, Appraisal, and Research (CEDAR) University of Warwick, Coventry, UK.
Centre for Developmental Psychiatry and Psychology, Monash University, Melbourne, Australia.

David Gillespie (D)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, UK.

Rhys Williams-Thomas (R)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, UK.

Lucy Brookes-Howell (L)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, UK.

Renee Romeo (R)

Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.

Janet Boadu (J)

Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.

Alka S Ahuja (AS)

Aneurin Bevan University Health Board, Newport, UK.

Anne Marie McKigney (AM)

Aneurin Bevan University Health Board, Newport, UK.

Martin Knapp (M)

Department of Social Policy, London School of Economics, London, UK.

Kathryn Smith (K)

Mind Body Brain Connections Ltd, Threemilestone Industrial Estate, Truro, UK.

Jacqui Thornton (J)

Aneurin Bevan University Health Board, Newport, UK.

Gemma Warren (G)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH